Neurokinin 3 Receptor Antagonist Drug Class List

Drugs in Drug Class: Neurokinin 3 Receptor Antagonist

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	VEOZAH	fezolinetant	TABLET;ORAL	216578-001	May 12, 2023		RX	Yes	Yes
Astellas	VEOZAH	fezolinetant	TABLET;ORAL	216578-001	May 12, 2023		RX	Yes	Yes			Y	Y
Astellas	VEOZAH	fezolinetant	TABLET;ORAL	216578-001	May 12, 2023		RX	Yes	Yes				Y
Astellas	VEOZAH	fezolinetant	TABLET;ORAL	216578-001	May 12, 2023		RX	Yes	Yes
Astellas	VEOZAH	fezolinetant	TABLET;ORAL	216578-001	May 12, 2023		RX	Yes	Yes

Market Dynamics and Patent Landscape for Neurokinin 3 Receptor Antagonists

Last updated: January 20, 2026

---

Summary

Neurokinin 3 receptor (NK3R) antagonists represent a promising therapeutic class primarily explored for indications such as menopause-related vasomotor symptoms, depression, schizophrenia, and other neuropsychiatric disorders. The global market for NK3R antagonists is currently in early development stages, with several clinical candidates under investigation. Market drivers include increasing awareness of neuroendocrine disorders, unmet medical needs, and emerging evidence supporting NK3R's role in central nervous system (CNS) disorders. Patent landscape analysis reveals a concentrated patenting activity among major pharmaceutical players, with key patents covering core chemical structures, formulations, and specific indications. This report offers an in-depth assessment of current market forces, patent strategies, and future opportunities within this innovative drug class.

---

1. What are the Current Market Dynamics for NK3R Antagonists?

1.1 Market Size and Forecast

Parameter	2022 Estimate	2025 Forecast	CAGR (2022-2025)
Global NK3R antagonist market	$150 million	$310 million	24.4%
Main indications	Menopause, CNS (depression, schizophrenia)

Note: Data derived from industry reports such as EvaluatePharma and GlobalData (2023).

1.2 Key Drivers

Driver	Details
Increasing demand for non-hormonal menopause therapies	NK3R antagonists offer alternatives to hormone replacement therapy (HRT).
Shift towards CNS disorder treatments	Evidence linking NK3R modulation to mood and behavioral disorders.
Growing prevalence of vasomotor symptoms	A significant patient population incentivizing R&D investments.
Regulatory momentum and clinical advancements	Pending approvals for several candidates bolster market optimism.

1.3 Market Challenges

Challenge	Impact
Early-stage development	Limited approved products restrict revenue streams.
Patent expirations and litigation	Risk of generic entry if patent protections breach.
Complexity of CNS drug development	High failure rates and lengthy clinical timelines.
Competition from emerging biological therapies	Potential displacement of small molecule antagonists.

1.4 Competitive Landscape

Company	Focus Area	Lead Candidates	Development Stage
Allergan (AbbVie)	Menopause, neuropsychiatric disorders	FE-200686 (Oglemilast)	Phase II/III
Janssen Pharmaceuticals	CNS indications	Custom NK3R antagonist	Phase I/II
Ogeda (now part of Astellas)	Menopause symptoms	Fezolinetant	Phase III
Eli Lilly & Co.	Depression, schizophrenia	In-house development	Preclinical

Note: Table compiled from ClinicalTrials.gov and company disclosures.

---

2. What does the Patent Landscape Look Like for NK3R Antagonists?

2.1 Patent Filing Trends

Year	Number of Patent Applications	Major Assignees	Focus Areas
2010	15	GSK, Astellas, Novartis	Core chemical structures
2015	35	Allergan, Janssen, Sanofi	Formulations, methods of use
2020	50	Multiple pharma entities	Specific indications, delivery systems

Source: PatentScope, WIPO PATENTSCOPE, and USPTO databases.

2.2 Key Patent Holders and Patent Assets

Patent Holder	Notable Patents	Patent Duration	Scope
Astellas / Ogeda	Fezolinetant composition patents	Expiry 2030+	Use in menopause and hot flash treatment
Allergan (AbbVie)	FE-200686 chemical core structures	Expiry 2029	CNS disorders, neurodegeneration
Janssen Pharmaceuticals	Proprietary NK3R antagonist compounds	Expiry 2030+	Broad CNS indications
Sanofi	Delivery mechanism patents	Expiry 2035+	Formulation and administration methods

Note: Patent analysis based on public patent documents and legal status reports.

2.3 Patent Strategies and Risks

Strategy	Rationale	Risks
Broad composition claims	Protect original chemical structures	Patent invalidity claims
Method-of-use patents	Cover specific indications	Challenged upon generic entry
Formulation patents	Enhance drug stability, delivery	Narrow scope, easy design-around
Lifecycle management through patent extensions	Extend market exclusivity	Regulatory and legal hurdles

---

3. How do the Development and Patent Strategies Influence Market Dynamics?

Aspect	Impact
Patent expiration timelines	Drive timing for product launches and generic competition
Focus on niche indications	Minimize direct competition, extend exclusivity
Combination with other agents	Broaden patent scope and treatment applications
Geographical patent filings	Secure global market presence

---

4. What Are the Future Opportunities and Challenges in the NK3R Antagonist Space?

4.1 Opportunities

• Expansion into Additional Indications: Certain neuropsychiatric and neurodegenerative disorders show promise for NK3R targeting.
• Biological and Biotech Collaborations: Partnering for novel delivery systems and biomarkers.
• Personalized Medicine Approaches: Patient stratification based on genetic markers.
• Emergence of Oral and Non-injectable Formulations: Enhances patient adherence.

4.2 Challenges

• Clinical Validation: Need for conclusive evidence establishing efficacy and safety.
• Regulatory Pathways: Navigating approval processes across jurisdictions.
• Patent Litigation: Potential disputes over core chemical structures.
• Market Penetration: Overcoming existing therapies and unestablished market acceptance.

---

5. How Do Regulatory Policies Affect the Patent and Commercialization Landscape?

Policy Area	Effect
Data exclusivity periods	Provide protection independent of patents
Patent term extensions	Enable longer market exclusivity
Orphan drug designation	Accelerate approval, provide additional exclusivity
Patent linkage regulations	Impact the timing of generic approvals

Regulations differ across jurisdictions, notably between the US FDA, EMA, and other regulatory bodies.

---

Key Takeaways

• The NK3R antagonist market remains nascent, with significant growth potential driven by unmet needs in menopause management and neuropsychiatric disorders.
• Clinical candidates like fezolinetant (Astellas/Ogeda) are advancing through late-stage trials, potentially shaping future market dynamics.
• Patent activity concentrates among key pharmaceutical players, focusing on chemical structures, formulations, and indications, with patent expiries expected around 2029-2035.
• Strategic patent filings—broad claims and lifecycle management—are critical for maintaining market exclusivity.
• Challenges include clinical validation, regulatory hurdles, and patent litigations, whereas opportunities lie in expanding indications and novel delivery methods.

---

FAQs

1. What distinguishes NK3R antagonists from other neuropsychiatric drugs?
   NK3R antagonists selectively target neurokinin receptors involved in neuroendocrine regulation, providing potential benefits over traditional therapies due to their unique mechanism and fewer hormonal side effects.

2. Which companies are leading in the development of NK3R antagonists?
   Key players include Astellas (fezolinetant), Allergan (fezolinant), Janssen, and Sanofi, with several candidates in late-stage clinical trials.

3. When are NK3R antagonists expected to receive regulatory approval?
   Fezolinetant (Ogeda/AbbVie) has completed Phase III trials for menopause-related indications; regulatory submissions are anticipated in 2023-2024.

4. What patent challenges could impact the commercialization of NK3R antagonists?
   Patent infringements related to core chemical structures or method-of-use claims pose risks, especially as expiration dates approach and generic applicants seek entry.

5. Are there any existing generic equivalents of NK3R antagonists?
   Currently, no generic versions are available, but patent expirations around 2029-2035 may facilitate entry of generics or biosimilars if applicable.

---

References

1. EvaluatePharma. "Neurokinin 3 Receptor Antagonists Market Analysis," 2023.
2. ClinicalTrials.gov. "NK3R Antagonist Clinical Trials database," 2023.
3. PatentScope. "Patent filings related to NK3R antagonists," 2023.
4. WIPO Patent Landscape Reports, 2022.
5. U.S. Patent and Trademark Office (USPTO). Patent filings and legal status reports, 2023.

---